Zymeworks Inc (ZYME) Buy Rating Maintained Today By Canaccord Genuity; The Target Given is $21.0000

Zymeworks Inc (ZYME) Rating Reaffirmed

In a report sent to clients and investors on 28 November, The Buy rating of Zymeworks Inc (ZYME) shares was maintained by Canaccord Genuity, who now has a $21.0000 target price on the stock. Canaccord Genuity’s target price would suggest a possible upside of 63.17 % from the last stock price of the company.

Zymeworks Inc. (NYSE:ZYME) Ratings Coverage

Among 4 analysts covering Zymeworks (ZYME), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zymeworks has $37 highest and $19 lowest target. $26’s average target is 102.02% above currents $12.87 stock price. Zymeworks had 6 analyst reports since June 4, 2018 according to SRatingsIntel. Raymond James maintained the stock with “Outperform” rating in Tuesday, June 5 report. The firm has “Hold” rating given on Wednesday, June 6 by Citigroup. The stock of Zymeworks Inc. (NYSE:ZYME) earned “Buy” rating by Canaccord Genuity on Wednesday, November 28. Citigroup upgraded the stock to “Buy” rating in Thursday, August 2 report. The firm earned “Neutral” rating on Thursday, June 21 by Citigroup. The stock of Zymeworks Inc. (NYSE:ZYME) has “Outperform” rating given on Monday, June 4 by Wells Fargo.

The stock decreased 1.08% or $0.14 during the last trading session, reaching $12.87. About 106,339 shares traded. Zymeworks Inc. (ZYME) has risen 74.85% since December 2, 2017 and is uptrending. It has outperformed by 59.23% the S&P500.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company has market cap of $418.57 million. The company's lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It currently has negative earnings. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers.

More notable recent Zymeworks Inc. (NYSE:ZYME) news were published by: Fool.ca which released: “3 Stocks at 52-Week Highs: Should You Take Profits or Keep Stacking? – The Motley Fool Canada” on June 01, 2018, also Streetinsider.com with their article: “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 – StreetInsider.com” published on November 14, 2018, Investingnews.com published: “Zymeworks Makes First Dermatology Licensing Deal | INN – Investing News Network” on October 24, 2018. More interesting news about Zymeworks Inc. (NYSE:ZYME) were released by: Businesswire.com and their article: “Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies – Business Wire” published on May 14, 2018 as well as Prnewswire.com‘s news article titled: “Zymeworks (ZYME) Alert: Johnson Fistel Announces Investigation of Zymeworks Inc.; Encourages Investors to Contact the Firm for Additional Information – PR Newswire” with publication date: December 15, 2017.

Zymeworks Inc. (NYSE:ZYME) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.